An interventional study of recreational fishing (angling) in Angling, Supportive Therapeutic and Schizophrenia, sponsored by Firat University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-07.
Sponsored by Firat University · Not applicable, Interventional, and Supportive care
This study aims to evaluate the effects of recreational fishing (angling) as a supportive therapeutic intervention in individuals diagnosed with schizophrenia. Schizophrenia is a chronic psychiatric disorder characterized by disturbances in thinking, perception, emotion, and behavior, often accompanied by negative symptoms such as social withdrawal, anhedonia, and cognitive impairment, which significantly reduce quality of life.
Recreational activities, particularly those involving nature-based engagement, have been shown to support psychological well-being through stress reduction, improved attention, and enhanced mood regulation. Angling is considered a mindfulness-like recreational activity that promotes relaxation, concentration, and emotional regulation, potentially offering benefits for individuals with psychiatric conditions.
In this randomized controlled study, participants with schizophrenia will engage in a structured recreational fishing program in addition to standard care. The effects of the intervention will be evaluated on biochemical serum parameters, anxiety and depression levels, and quality of life outcomes. The study also aims to assess the psychosocial well-being of participants and determine the feasibility of integrating angling as an adjunctive non-pharmacological intervention in schizophrenia care.
The findings are expected to contribute to evidence-based complementary treatment approaches in psychiatric rehabilitation.
3,563 studies on the registry are indexed under Schizophrenia; 491 are open to participants now.
This study's planned enrollment of 60 is below the median of 71 across 2,944 interventional studies indexed under Schizophrenia.
Browse Schizophrenia studies →Firat University is the lead sponsor of 117 studies on the registry; 46 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Behavioral: recreational fishing (angling)
Fishing will be done.
The Positive and Negative Syndrome Scale
The Positive and Negative Syndrome Scale : he Positive and Negative Syndrome Scale (PANSS), developed by Kay et al., is a semi-structured clinician-rated instrument consisting of 30 items scored on a 7-point scale (1 = absent to 7 = extreme). The scale comprises three subscales: positive symptoms (7 items; score range: 7-49), negative symptoms (7 items; score range: 7-49), and general psychopathology (16 items; score range: 16-112). Total PANSS scores range from 30 to 210, with higher scores indicating more severe psychopathology and poorer clinical status.
Time frame: Baseline and immediately after the 8-week intervention.
Quality of Life Scale for Schizophrenia Patients
Developed by Heinrich et al. to assess the quality of life of schizophrenia patients, the Turkish validity and reliability study was conducted by Soygür et al. Administered in a semi-structured interview format, the scale evaluates the individual's symptoms and level of functioning over the past four weeks. It consists of 21 items and four sub-dimensions: interpersonal relationships, occupational role, mental symptoms, and daily activities. Scores on the scale range from 0 to 126, with higher scores indicating better quality of life.
Time frame: Baseline and immediately after the 8-week intervention.
UCLA Loneliness Scale
The UCLA Loneliness Scale-Short Form (ULS-8) is an 8-item self-report instrument used to assess perceived loneliness. Each item is rated on a 4-point Likert scale ranging from 1 ("Never") to 4 ("Always"). Two items are reverse scored. Total scores range from 8 to 32, with higher scores indicating greater perceived loneliness.
Time frame: Baseline and immediately after the 8-week intervention.
Serum Beta-Endorphin Concentration
Venous blood samples will be collected to measure serum beta-endorphin concentration. Changes in serum beta-endorphin levels will be evaluated to assess the biological effects of the intervention.
Time frame: Baseline and immediately after the 8-week intervention.
Serum Serotonin Concentration
Venous blood samples will be collected to measure serum serotonin concentration. Changes in serum serotonin levels will be evaluated to assess the biological effects of the intervention.
Time frame: Baseline and immediately after the 8-week intervention.
Serum Cortisol Concentration
Venous blood samples will be collected to measure serum cortisol concentration. Changes in serum cortisol levels will be evaluated to assess the biological effects of the intervention.
Time frame: Baseline and immediately after the 8-week intervention.
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2026 (actual). Primary completion is estimated for Jul 2026, 1 month after the start.
Of 753 non-industry interventional studies with no phase under Schizophrenia, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 56. This study's planned 1 month is below that.
Counting every sponsor, half of 766 studies reached it within 32 months; a quarter within 16 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.